A Johnson & Johnson unit has filed for Swiss approval to sell ceftobiprole, marketed in partnership with developer Basilea Pharmaceutical, as a treatment for diabetic foot infections. The drug already is on the Swiss fast track for possible treatment of skin and soft-tissue infections, and it's under review by regulators in the U.S., Canada, and the E.U.
- see this announcement [1]
- read the AFX report [2]
Related Articles:
J&J makes big cuts at Alza and Scios. Report [3]
&J restructures pharma unit, laying off workers. Report [4]
Links:
[1] http://www.fiercebiotech.com/press-releases/press-release-basilea-announces-submission-marketing-authorization-application-ceftob
[2] http://www.forbes.com/markets/feeds/afx/2007/08/23/afx4046709.html
[3] http://www.fiercebiotech.com/story/j-j-makes-big-cuts-alza-and-scios/2007-08-01
[4] http://www.fiercebiotech.com/story/j-j-restructures-pharma-unit-laying-workers/2007-07-31